Dermatologic Clinic, Department of Medicine and Ageing Science, University G. D'Annunzio Chieti-Pescara, Chieti, Italy.
Dermatology Clinic/ASF Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
J Dermatolog Treat. 2022 Feb;33(1):443-448. doi: 10.1080/09546634.2020.1762840. Epub 2020 Jun 22.
Although molluscum contagiosum virus (MCV) infection is a common disease widespread among children and young adults, there is no shared opinion on treatment that can be divided into physical, chemical, medical (immunomodulating or anti-viral). According to some authors, MCV is best left to clear by itself.
To assess the clearance of MCV lesions in a sample of pediatric patients. It compares outcomes in treated with Imiquimod cream, compared with non-treated patients.
The sample consits of 48 pediatric patients affected by MVC clinically diagnosed. It was divided into two groups: Group I, treated with Imiquimod 5% cream once/day until the onset of a visible inflammatory reaction. Once the reaction was illicited, application was suspended until the irritation resolved. If the lesion was still present, drug was administered again using the same regimen. The cycle was repeated until complete clinical resolution. Group II, control, comprises non-treated patients. Follow up visits were carried out 12, 16, 20, 48, and 52 weeks from the beginning of treatment.
At week 20, all patients except one in the treated group were lesion free. Persistence of MCV lesions was documented in one patient only until week 48. In the control group all patients were still affected by MCV lesions during the follow-up period. Spontaneous clinical resolution of the infection was observed in only 2 patients at week 52. The results of the study show Imiquimod's significant efficacy.
Our study is one of the few case-control studies in pediatric population carried out with such long-term follow-up. Efficacy of this personalized treatment, scarce recurrence, absence of cicatricial sequelae and lack of necessity for deep sedation, in the case of children with disseminated lesions, makes the use of Imiquimod the first line of treatment compared with other destructive treatments or with no-treatment at all.
虽然传染性软疣病毒（MCV）感染是一种常见的儿童和青年人群中的疾病，但对于治疗方法尚无共识，治疗方法可分为物理、化学、医学（免疫调节或抗病毒）。根据一些作者的观点，MCV 最好自行清除。
评估在儿科患者样本中 MCV 病变的清除情况。比较咪喹莫特乳膏治疗与未治疗患者的结果。
该样本包括 48 例经临床诊断患有 MVC 的儿科患者。将其分为两组：I 组，用咪喹莫特 5%乳膏每天一次治疗，直到出现可见的炎症反应。一旦出现反应，暂停用药，直到刺激消退。如果病变仍然存在，再次使用相同方案给药。该周期重复，直到完全临床缓解。II 组，对照组，包括未治疗患者。在治疗开始后 12、16、20、48 和 52 周进行随访。
在第 20 周时，治疗组除 1 例患者外，所有患者的病变均消失。仅在第 48 周时记录到 1 例患者的 MCV 病变持续存在。在对照组中，所有患者在随访期间仍患有 MCV 病变。只有 2 例患者在第 52 周时观察到感染的自发临床缓解。该研究的结果表明咪喹莫特的疗效显著。
我们的研究是在儿科人群中进行的少数病例对照研究之一，随访时间如此之长。这种个体化治疗的疗效、罕见复发、无瘢痕后遗症以及在儿童患有播散性病变时无需深度镇静的情况下，使咪喹莫特的使用成为与其他破坏性治疗或不治疗相比的一线治疗方法。
